Arthur Christopoulos

List of Publications by Year in Descending Order

346 papers	24,134 citations	77 h-index	143 g-index
395 ext. papers	27,636 ext. citations	10.1 avg, IF	7.21 L-index

#	Paper	IF	Citations
346	Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation.. *Nature Communications*, **2022**, 13, 92	17.4	3
345	A structural basis for amylin receptor phenotype.. *Science*, **2022**, 375, eabm9609	33.3	0
344	Neurological, neuropsychiatric and neurodevelopmental complications of COVID-19. *Australian and New Zealand Journal of Psychiatry*, **2021**, 55, 750-762	2.6	13
343	From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease. *Cell*, **2021**, 184, 5886-5901.e22	56.2	8
342	Defining and unpacking the core concepts of pharmacology education. *Pharmacology Research and Perspectives*, **2021**, 9, e00894	3.1	3
341	Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms. *BMJ Open Diabetes Research and Care*, **2021**, 9,	4.5	2
340	Cognitive behavioral markers of neurodevelopmental trajectories in rodents. *Translational Psychiatry*, **2021**, 11, 556	8.6	1
339	Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. *Frontiers in Pharmacology*, **2021**, 12, 628060	5.6	1
338	A robust method for particulate detection of a genetic tag for 3D electron microscopy. *ELife*, **2021**, 10,	8.9	8
337	Structure and dynamics of the CGRP receptor in apo and peptide-bound forms. *Science*, **2021**, 372,	33.3	21
336	Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity. *PLoS Biology*, **2021**, 19, e3001295	9.7	8
335	Development of Novel 4-Arylpyridin-2-one and 6-Arylpyrimidin-4-one Positive Allosteric Modulators of the M Muscarinic Acetylcholine Receptor. *ChemMedChem*, **2021**, 16, 216-233	3.7	3
334	Identification of a Novel Allosteric Site at the M Muscarinic Acetylcholine Receptor. *ACS Chemical Neuroscience*, **2021**, 12, 3112-3123	5.7	1
333	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets. *British Journal of Pharmacology*, **2021**, 178 Suppl 1, S1-S26	8.6	20
332	Positive allosteric mechanisms of adenosine A receptor-mediated analgesia. *Nature*, **2021**, 597, 571-576	50.4	12
331	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. *British Journal of Pharmacology*, **2021**, 178 Suppl 1, S27-S156	8.6	46
330	Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol.. *Frontiers in Endocrinology*, **2021**, 12, 789957	5.7	2

329	Probe dependence and biased potentiation of metabotropic glutamate receptor 5 is mediated by differential ligand interactions in the common allosteric binding site. *Biochemical Pharmacology*, **2020**, 177, 114013	6	4
328	Structure and Dynamics of Adrenomedullin Receptors AM and AM Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins. *ACS Pharmacology and Translational Science*, **2020**, 3, 263-284	5.9	42
327	Acetylcholine Muscarinic M Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents. *Biological Psychiatry*, **2020**, 88, 898-909	7.9	10
326	Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs. *Nature Chemical Biology*, **2020**, 16, 240-249	11.7	19
325	Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation. *Molecular Cell*, **2020**, 77, 656-668.e5	17.6	46
324	Rational development of a high-affinity secretin receptor antagonist. *Biochemical Pharmacology*, **2020**, 177, 113929	6	2
323	Sustainable Pharmacy Education in the Time of COVID-19. *American Journal of Pharmaceutical Education*, **2020**, 84, ajpe8088	2.5	56
322	Differential contribution of metabotropic glutamate receptor 5 common allosteric binding site residues to biased allosteric agonism. *Biochemical Pharmacology*, **2020**, 177, 114011	6	4
321	Activation of the GLP-1 receptor by a non-peptidic agonist. *Nature*, **2020**, 577, 432-436	50.4	74
320	Mu and Delta Opioid Receptors Are Coexpressed and Functionally Interact in the Enteric Nervous System of the Mouse Colon. *Cellular and Molecular Gastroenterology and Hepatology*, **2020**, 9, 465-483	7.9	12
319	Evaluation of Operational Models of Agonism and Allosterism at Receptors with Multiple Orthosteric Binding Sites. *Molecular Pharmacology*, **2020**, 97, 35-45	4.3	6
318	Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. *Molecular Cell*, **2020**, 80, 485-500.e7	17.6	41
317	Restoring Agonist Function at a Chemogenetically Modified M Muscarinic Acetylcholine Receptor. *ACS Chemical Neuroscience*, **2020**, 11, 4270-4279	5.7	0
316	Structure and dynamics of the active Gs-coupled human secretin receptor. *Nature Communications*, **2020**, 11, 4137	17.4	26
315	Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias. *Frontiers in Pharmacology*, **2020**, 11, 606656	5.6	7
314	Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor. *Molecular Pharmacology*, **2019**, 95, 245-259	4.3	2
313	Deconvoluting the Molecular Control of Binding and Signaling at the Amylin 3 Receptor: RAMP3 Alters Signal Propagation through Extracellular Loops of the Calcitonin Receptor. *ACS Pharmacology and Translational Science*, **2019**, 2, 183-197	5.9	7
312	Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology. *Neuropharmacology*, **2019**, 149, 83-96	5.5	13

311	Subtle Modifications to the Indole-2-carboxamide Motif of the Negative Allosteric Modulator N-((trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1 H)-yl)ethyl)cyclohexyl)-1 H-indole-2-carboxamide (SB269652) Yield Dramatic Changes in Pharmacological Activity at the Dopamine D Receptor. *Journal of Medicinal Chemistry*, **2019**, 62, 371-377	8.3	10
310	Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. *Nature Communications*, **2019**, 10, 3289	17.4	24
309	Molecular Determinants of the Intrinsic Efficacy of the Antipsychotic Aripiprazole. *ACS Chemical Biology*, **2019**, 14, 1780-1792	4.9	14
308	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. *British Journal of Pharmacology*, **2019**, 176 Suppl 1, S21-S141	8.6	391
307	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. *British Journal of Pharmacology*, **2019**, 176 Suppl 1, S1-S20	8.6	218
306	Acetylcholine receptors (muscarinic) (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. *IUPHAR/BPS Guide To Pharmacology CITE*, **2019**, 2019,	1.7	2
305	Crystal structure of the M muscarinic acetylcholine receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 26001-26007	11.5	27
304	6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M mAChR: The Determinants of Allosteric Activity. *ACS Chemical Neuroscience*, **2019**, 10, 1099-1114	5.7	6
303	The Molecular Control of Calcitonin Receptor Signaling. *ACS Pharmacology and Translational Science*, **2019**, 2, 31-51	5.9	30
302	Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H receptor antagonists. *Neuropharmacology*, **2019**, 144, 244-255	5.5	17
301	Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. *Nature*, **2018**, 555, 121-125	50.4	190
300	Discovery and Optimization of Potent and CNS Penetrant M-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold. *ACS Chemical Neuroscience*, **2018**, 9, 1572-1581	5.7	7
299	New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism. *British Journal of Pharmacology*, **2018**, 175, 4036-4046	8.6	33
298	Structure-Activity Relationships of Pan-G-Coupled Muscarinic Acetylcholine Receptor Positive Allosteric Modulators. *ACS Chemical Neuroscience*, **2018**, 9, 1818-1828	5.7	5
297	A Structure-Activity Relationship Study of Bitopic N-Substituted Adenosine Derivatives as Biased Adenosine A Receptor Agonists. *Journal of Medicinal Chemistry*, **2018**, 61, 2087-2103	8.3	21
296	Correspondence: Reply to Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury. *Nature Communications*, **2018**, 9, 530	17.4	4
295	Structure-based discovery of selective positive allosteric modulators of antagonists for the M muscarinic acetylcholine receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E2419-E2428	11.5	38
294	Muscarinic M receptors modulate ethanol seeking in rats. *Neuropsychopharmacology*, **2018**, 43, 1510-1518	7.7	19

293	To Bind or Not to Bind: Unravelling GPCR Polypharmacology. *Cell*, **2018**, 172, 636-638	56.2	14
292	The action of a negative allosteric modulator at the dopamine D receptor is dependent upon sodium ions. *Scientific Reports*, **2018**, 8, 1208	4.9	13
291	Characterization of signalling and regulation of common calcitonin receptor splice variants and polymorphisms. *Biochemical Pharmacology*, **2018**, 148, 111-129	6	13
290	The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D receptor. *Biochemical Pharmacology*, **2018**, 148, 315-328	6	18
289	Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism. *Journal of Biological Chemistry*, **2018**, 293, 9370-9387	5.4	32
288	Identification of Global and Ligand-Specific Calcium Sensing Receptor Activation Mechanisms. *Molecular Pharmacology*, **2018**, 93, 619-630	4.3	13
287	Bitopic Binding Mode of an M Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. *Molecular Pharmacology*, **2018**, 93, 645-656	4.3	20
286	Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity. *British Journal of Pharmacology*, **2018**, 175, 4095-4108	8.6	18
285	Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M Muscarinic Acetylcholine Receptors. *Molecular Pharmacology*, **2018**, 94, 770-783	4.3	8
284	Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M Muscarinic Acetylcholine Receptor with Weak Agonist Activity and Diverse Modulatory Profiles. *Journal of Medicinal Chemistry*, **2018**, 61, 2875-2894	8.3	10
283	Recent advances in the determination of G protein-coupled receptor structures. *Current Opinion in Structural Biology*, **2018**, 51, 28-34	8.1	39
282	Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. *Biochemical Pharmacology*, **2018**, 150, 214-244	6	18
281	DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs and. *ACS Pharmacology and Translational Science*, **2018**, 1, 61-72	5.9	76
280	Dominant Negative G Proteins Enhance Formation and Purification of Agonist-GPCR-G Protein Complexes for Structure Determination. *ACS Pharmacology and Translational Science*, **2018**, 1, 12-20	5.9	41
279	Mechanisms of signalling and biased agonism in G protein-coupled receptors. *Nature Reviews Molecular Cell Biology*, **2018**, 19, 638-653	48.7	244
278	Structure of the adenosine-bound human adenosine A receptor-G complex. *Nature*, **2018**, 558, 559-563	50.4	188
277	The International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR): Relevance to pharmacology today and challenges for the future. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO2-8-10	0	
276	Adenosine G Protein-Coupled Receptor Biased Agonism to Treat Ischemic Heart Disease. *FASEB Journal*, **2018**, 32, 555.19	0.9	

275	Structural Basis for Binding of Allosteric Drug Leads in the Adenosine A Receptor. *Scientific Reports*, **2018**, 8, 16836	4.9	38
274	Utility of an "Allosteric Site-Impaired" M Muscarinic Acetylcholine Receptor as a Novel Construct for Validating Mechanisms of Action of Synthetic and Putative Endogenous Allosteric Modulators. *Molecular Pharmacology*, **2018**, 94, 1298-1309	4.3	2
273	Dual Action Calcium-Sensing Receptor Modulator Unmasks Novel Mode-Switching Mechanism. *ACS Pharmacology and Translational Science*, **2018**, 1, 96-109	5.9	10
272	Rules of Engagement: GPCRs and G Proteins. *ACS Pharmacology and Translational Science*, **2018**, 1, 73-83	5.9	62
271	Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists. *Biochemical Pharmacology*, **2018**, 156, 406-419	6	27
270	Cryo-EM structure of the active, G-protein complexed, human CGRP receptor. *Nature*, **2018**, 561, 492-497	50.4	141
269	Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors. *Journal of General Physiology*, **2018**, 150, 1360-1372	3.4	20
268	Differential engagement of polar networks in the glucagon-like peptide 1 receptor by endogenous variants of the glucagon-like peptide 1. *Biochemical Pharmacology*, **2018**, 156, 223-240	6	5
267	Probing the binding site of novel selective positive allosteric modulators at the M muscarinic acetylcholine receptor. *Biochemical Pharmacology*, **2018**, 154, 243-254	6	11
266	Structural insights into G-protein-coupled receptor allostery. *Nature*, **2018**, 559, 45-53	50.4	154
265	Allostery and Biased Agonism at Class B G Protein-Coupled Receptors. *Chemical Reviews*, **2017**, 117, 111[illegible]	[illegible]	64
264	Isoform-Specific Biased Agonism of Histamine H3 Receptor Agonists. *Molecular Pharmacology*, **2017**, 91, 87-99	4.3	16
263	Structure of the Adenosine A Receptor Reveals the Basis for Subtype Selectivity. *Cell*, **2017**, 168, 867-877	36.13	167
262	Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. *Nature*, **2017**, 546, 118-123	50.4	334
261	Capadenoson, a clinically trialed partial adenosine A receptor agonist, can stimulate adenosine A receptor biased agonism. *Biochemical Pharmacology*, **2017**, 135, 79-89	6	31
260	High throughput, quantitative analysis of human osteoclast differentiation and activity. *Analytical Biochemistry*, **2017**, 519, 51-56	3.1	6
259	Structure-Based Design and Discovery of New M Receptor Agonists. *Journal of Medicinal Chemistry*, **2017**, 60, 9239-9250	8.3	16
258	Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. *Nature Communications*, **2017**, 8, 14232	17.4	70

257	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. *British Journal of Pharmacology*, **2017**, 174 Suppl 1, S17-S129	8.6	517
256	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. *British Journal of Pharmacology*, **2017**, 174 Suppl 1, S1-S16	8.6	231
255	Structural features embedded in G protein-coupled receptor co-crystal structures are key to their success in virtual screening. *PLoS ONE*, **2017**, 12, e0174719	3.7	9
254	Improving virtual screening of G protein-coupled receptors via ligand-directed modeling. *PLoS Computational Biology*, **2017**, 13, e1005819	5	7
253	A kinetic view of GPCR allostery and biased agonism. *Nature Chemical Biology*, **2017**, 13, 929-937	11.7	89
252	Allosteric modulation as a unifying mechanism for receptor function and regulation. *Diabetes, Obesity and Metabolism*, **2017**, 19 Suppl 1, 4-21	6.7	31
251	Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery. *Neuropharmacology*, **2017**, 115, 60-72	5.5	34
250	M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. *Journal of Clinical Investigation*, **2017**, 127, 487-499	15.9	39
249	Microglial activation and progressive brain changes in schizophrenia. *British Journal of Pharmacology*, **2016**, 173, 666-80	8.6	126
248	The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling. *Biochemical Pharmacology*, **2016**, 117, 46-56	6	22
247	Key interactions by conserved polar amino acids located at the transmembrane helical boundaries in Class B GPCRs modulate activation, effector specificity and biased signalling in the glucagon-like peptide-1 receptor. *Biochemical Pharmacology*, **2016**, 118, 68-87	6	32
246	Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators. *Molecular Pharmacology*, **2016**, 90, 427-36	4.3	18
245	Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation. *Cell*, **2016**, 166, 1084-1102	56.2	164
244	The role of kinetic context in apparent biased agonism at GPCRs. *Nature Communications*, **2016**, 7, 10842	17.4	206
243	Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 359, 354-365	4.7	15
242	Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor. *Molecular Pharmacology*, **2016**, 90, 12-22	4.3	31
241	The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism. *Cell*, **2016**, 165, 1632-1643	56.2	102
240	Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor. *Biochemical Pharmacology*, **2016**, 113, 70-87	6	44

239	Use of Cysteine Trapping to Map Spatial Approximations between Residues Contributing to the Helix N-capping Motif of Secretin and Distinct Residues within Each of the Extracellular Loops of Its Receptor. *Journal of Biological Chemistry*, **2016**, 291, 5172-84	5.4	8
238	Novel Fused Arylpyrimidinone Based Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor. *ACS Chemical Neuroscience*, **2016**, 7, 647-61	5.7	13
237	Prediction of Loops in G Protein-Coupled Receptor Homology Models: Effect of Imprecise Surroundings and Constraints. *Journal of Chemical Information and Modeling*, **2016**, 56, 671-86	6.1	6
236	Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. *Cell Research*, **2016**, 26, 574-92	24.7	56
235	Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 357, 36-44	4.7	40
234	Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors. *ACS Chemical Biology*, **2016**, 11, 1220-9	4.9	43
233	Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. *Nature*, **2016**, 531, 335-40	50.4	211
232	4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor. *Journal of Medicinal Chemistry*, **2016**, 59, 388-409	8.3	32
231	A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures. *Molecular Pharmacology*, **2016**, 89, 335-47	4.3	43
230	Quantification of adenosine A(1) receptor biased agonism: Implications for drug discovery. *Biochemical Pharmacology*, **2016**, 99, 101-12	6	44
229	Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants. *PLoS ONE*, **2016**, 11, e0146846	3.7	35
228	Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy. *Molecular Pharmacology*, **2016**, 90, 703-714	4.3	39
227	Role of the Second Extracellular Loop of the Adenosine A1 Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity. *Molecular Pharmacology*, **2016**, 90, 715-725	4.3	35
226	Novel Irreversible Agonists Acting at the A Adenosine Receptor. *Journal of Medicinal Chemistry*, **2016**, 59, 11182-11194	8.3	15
225	Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 5 Based on Select Acetylenic Negative Allosteric Modulators. *ACS Chemical Biology*, **2016**, 11, 1870-9	4.9	21
224	Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E5675-84	11.5	69
223	The complexity of signalling mediated by the glucagon-like peptide-1 receptor. *Biochemical Society Transactions*, **2016**, 44, 582-8	5.1	19
222	Ligand-Dependent Modulation of G Protein Conformation Alters Drug Efficacy. *Cell*, **2016**, 167, 739-749.e11	36.1	94

221	VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model. *Clinical and Experimental Pharmacology and Physiology*, **2016**, 43, 976-82	3	15
220	Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias. *Trends in Pharmacological Sciences*, **2015**, 36, 215-25	13.2	36
219	Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor. *Molecular Pharmacology*, **2015**, 88, 368-79	4.3	101
218	Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor. *Journal of Medicinal Chemistry*, **2015**, 58, 5287-307	8.3	32
217	Novel Allosteric Modulators of G Protein-coupled Receptors. *Journal of Biological Chemistry*, **2015**, 290, 19478-88	5.4	128
216	Detection and quantification of allosteric modulation of endogenous m4 muscarinic acetylcholine receptor using impedance-based label-free technology in a neuronal cell line. *Journal of Biomolecular Screening*, **2015**, 20, 646-54		7
215	Synthesis and pharmacological evaluation of M4 muscarinic receptor positive allosteric modulators derived from VU10004. *ACS Chemical Neuroscience*, **2015**, 6, 838-44	5.7	15
214	Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor. *Journal of Medicinal Chemistry*, **2015**, 58, 4220-9	8.3	46
213	Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery. *Journal of Pharmacology and Experimental Therapeutics*, **2015**, 353, 52-63	4.7	14
212	Endogenous allosteric modulators of G protein-coupled receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2015**, 353, 246-60	4.7	97
211	A structure-activity relationship study of the positive allosteric modulator LY2033298 at the M4 muscarinic acetylcholine receptor. *MedChemComm*, **2015**, 6, 1998-2003	5	6
210	Biased Agonism of Endogenous Opioid Peptides at the κ-Opioid Receptor. *Molecular Pharmacology*, **2015**, 88, 335-46	4.3	76
209	Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand. *Journal of Medicinal Chemistry*, **2015**, 58, 6819-43	8.3	40
208	A Positive Allosteric Modulator of the Adenosine A1 Receptor Selectively Inhibits Primary Afferent Synaptic Transmission in a Neuropathic Pain Model. *Molecular Pharmacology*, **2015**, 88, 460-8	4.3	29
207	Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists. *Molecular Pharmacology*, **2015**, 88, 779-90	4.3	15
206	Novel GPCR paradigms at the δ-opioid receptor. *British Journal of Pharmacology*, **2015**, 172, 287-96	8.6	48
205	Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics. *British Journal of Pharmacology*, **2015**, 172, 185-200	8.6	57
204	Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding. *Molecular Pharmacology*, **2015**, 87, 130-40	4.3	8

203	Receptor expression modulates calcium-sensing receptor mediated intracellular Ca2+ mobilization. *Endocrinology*, **2015**, 156, 1330-42	4.8	18
202	Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex. *Journal of Medicinal Chemistry*, **2015**, 58, 9562-77	8.3	15
201	Proof of concept study for designed multiple ligands targeting the dopamine D2, serotonin 5-HT2A, and muscarinic M1 acetylcholine receptors. *Journal of Medicinal Chemistry*, **2015**, 58, 1550-5	8.3	9
200	Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor. *Journal of Biological Chemistry*, **2014**, 289, 6067-79	5.4	46
199	Allosteric targeting of receptor tyrosine kinases. *Nature Biotechnology*, **2014**, 32, 1113-20	44.5	61
198	Structural basis of receptor sulfotyrosine recognition by a CC chemokine: the N-terminal region of CCR3 bound to CCL11/eotaxin-1. *Structure*, **2014**, 22, 1571-81	5.2	51
197	Advances in G protein-coupled receptor allostery: from function to structure. *Molecular Pharmacology*, **2014**, 86, 463-78	4.3	149
196	Roles of intraloops-2 and -3 and the proximal C-terminus in signalling pathway selection from the human calcium-sensing receptor. *FEBS Letters*, **2014**, 588, 3340-6	3.8	11
195	Synthesis and pharmacological evaluation of analogues of benzyl quinolone carboxylic acid (BQCA) designed to bind irreversibly to an allosteric site of the M muscarinic acetylcholine receptor. *Journal of Medicinal Chemistry*, **2014**, 57, 5405-18	8.3	24
194	A new mechanism of allostery in a G protein-coupled receptor dimer. *Nature Chemical Biology*, **2014**, 10, 745-52	11.7	95
193	Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective. *Medicinal Research Reviews*, **2014**, 34, 1286-330	14.4	81
192	International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. *Pharmacological Reviews*, **2014**, 66, 918-47	22.5	156
191	Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D receptor. *Journal of Medicinal Chemistry*, **2014**, 57, 4924-39	8.3	60
190	Allosteric modulation of M1 muscarinic acetylcholine receptor internalization and subcellular trafficking. *Journal of Biological Chemistry*, **2014**, 289, 15856-66	5.4	24
189	Development of a photoactivatable allosteric ligand for the m1 muscarinic acetylcholine receptor. *ACS Chemical Neuroscience*, **2014**, 5, 902-7	5.7	8
188	Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites. *Molecular Pharmacology*, **2014**, 86, 116-23	4.3	19
187	Muscarinic acetylcholine receptors: novel opportunities for drug development. *Nature Reviews Drug Discovery*, **2014**, 13, 549-60	64.1	245
186	Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 4614-9	11.5	74

185	Tyrosine sulfation of chemokine receptor CCR2 enhances interactions with both monomeric and dimeric forms of the chemokine monocyte chemoattractant protein-1 (MCP-1).. *Journal of Biological Chemistry*, **2014**, 289, 13362	5.4	4
184	Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. *Molecular Pharmacology*, **2014**, 86, 106-15	4.3	31
183	Quantification of ligand bias for clinically relevant 2-adrenergic receptor ligands: implications for drug taxonomy. *Molecular Pharmacology*, **2014**, 85, 492-509	4.3	165
182	Engendering biased signalling from the calcium-sensing receptor for the pharmacotherapy of diverse disorders. *British Journal of Pharmacology*, **2014**, 171, 1142-55	8.6	29
181	Allosteric Modulation of Chemokine Receptors. *Topics in Medicinal Chemistry*, **2014**, 87-117	0.4	2
180	Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor. *Journal of Biological Chemistry*, **2014**, 289, 33701-11	5.4	40
179	Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor. *Journal of Biological Chemistry*, **2014**, 289, 23817-37	5.4	43
178	Functional and structural perspectives on allosteric modulation of GPCRs. *Current Opinion in Cell Biology*, **2014**, 27, 94-101	9	29
177	Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias. *PLoS ONE*, **2014**, 9, e92042	3.7	53
176	Emerging paradigms in GPCR allostery: implications for drug discovery. *Nature Reviews Drug Discovery*, **2013**, 12, 630-44	64.1	317
175	Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor. *Journal of Biological Chemistry*, **2013**, 288, 21082-21095	5.4	15
174	Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. *Nature*, **2013**, 503, 295-9	50.4	303
173	A structure-activity analysis of biased agonism at the dopamine D2 receptor. *Journal of Medicinal Chemistry*, **2013**, 56, 9199-221	8.3	72
172	Activation and allosteric modulation of a muscarinic acetylcholine receptor. *Nature*, **2013**, 504, 101-6	50.4	639
171	Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor. *Journal of Medicinal Chemistry*, **2013**, 56, 8196-200	8.3	19
170	Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M muscarinic acetylcholine receptor. *Molecular Pharmacology*, **2013**, 84, 425-37	4.3	25
169	Allosteric modulation of a chemogenetically modified G protein-coupled receptor. *Molecular Pharmacology*, **2013**, 83, 521-30	4.3	19
168	Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. *Biochemical Society Transactions*, **2013**, 41, 172-9	5.1	53

167	Supra-physiological efficacy at GPCRs: superstition or super agonists?. *British Journal of Pharmacology*, **2013**, 169, 353-6	8.6	21
166	Signalling bias in new drug discovery: detection, quantification and therapeutic impact. *Nature Reviews Drug Discovery*, **2013**, 12, 205-16	64.1	535
165	Bridging the gap: bitopic ligands of G-protein-coupled receptors. *Trends in Pharmacological Sciences* , **2013**, 34, 59-66	13.2	132
164	Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. *Cancer Cell*, **2013**, 23, 477-88	24.3	110
163	Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor. *Journal of Medicinal Chemistry*, **2013**, 56, 5151-72	8.3	49
162	Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. *ACS Chemical Neuroscience*, **2013**, 4, 1026-48	5.7	54
161	Measurements of ligand bias and functional affinity. *Nature Reviews Drug Discovery*, **2013**, 12, 483	64.1	49
160	Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite. *British Journal of Pharmacology*, **2013**, 169, 659-70	8.6	21
159	Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. *Molecular Pharmacology*, **2013**, 83, 822-34	4.3	66
158	Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators. *Endocrinology*, **2013**, 154, 1105-16	4.8	63
157	Tyrosine sulfation of chemokine receptor CCR2 enhances interactions with both monomeric and dimeric forms of the chemokine monocyte chemoattractant protein-1 (MCP-1). *Journal of Biological Chemistry*, **2013**, 288, 10024-10034	5.4	63
156	Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery. *Molecular Endocrinology*, **2013**, 27, 1234-44		28
155	Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 5211-6	11.5	158
154	CGRP/Adrenomedullin **2013**, 744-751		
153	Calcium-sensing receptor-dependent activation of CREB phosphorylation in HEK293 cells and human parathyroid cells. *American Journal of Physiology - Endocrinology and Metabolism*, **2013**, 304, E1097-104	6	22
152	A simple method to generate stable cell lines for the analysis of transient protein-protein interactions. *BioTechniques*, **2013**, 54, 217-21	2.5	11
151	Adenosine A1 Receptor Biased Agonism: A Novel Approach for Cardioprotective Therapeutics. *FASEB Journal*, **2013**, 27, lb617	0.9	
150	Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6-tetrahydropyridines as 5-HT$_{1A}$ agonists. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 2560-4	2.9	5

149	Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. *Journal of Medicinal Chemistry*, **2012**, 55, 1445-64	8.3	184
148	Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. *Molecular Pharmacology*, **2012**, 82, 1066-73	4.3	44
147	Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor. *Journal of Medicinal Chemistry*, **2012**, 55, 2367-75	8.3	44
146	Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. *Journal of Biological Chemistry* , **2012**, 287, 3659-73	5.4	25
145	Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. *Journal of Biological Chemistry*, **2012**, 287, 3642-58	5.4	74
144	A simple method for quantifying functional selectivity and agonist bias. *ACS Chemical Neuroscience*, **2012**, 3, 193-203	5.7	343
143	Consequences of splice variation on Secretin family G protein-coupled receptor function. *British Journal of Pharmacology*, **2012**, 166, 98-109	8.6	31
142	Design and receptor interactions of obligate dimeric mutant of chemokine monocyte chemoattractant protein-1 (MCP-1). *Journal of Biological Chemistry*, **2012**, 287, 14692-702	5.4	40
141	Structure-function studies of muscarinic acetylcholine receptors. *Handbook of Experimental Pharmacology*, **2012**, 29-48	3.2	14
140	The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. *Annual Review of Pharmacology and Toxicology*, **2012**, 52, 153-78	17.9	133
139	Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. *Endocrinology*, **2012**, 153, 1232-41	4.8	122
138	A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. *Journal of Biological Chemistry*, **2012**, 287, 650-659	5.4	91
137	Allosteric modulation of endogenous metabolites as an avenue for drug discovery. *Molecular Pharmacology*, **2012**, 82, 281-90	4.3	63
136	RAMPs as drug targets. *Advances in Experimental Medicine and Biology*, **2012**, 744, 61-74	3.6	8
135	Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects. *Molecular Pharmacology*, **2012**, 81, 41-52	4.3	93
134	Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 18607-12	11.5	54
133	Stimulus bias provides evidence for conformational constraints in the structure of a G protein-coupled receptor. *Journal of Biological Chemistry*, **2012**, 287, 37066-77	5.4	28
132	Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium-sensing receptor. *Endocrinology*, **2012**, 153, 4304-16	4.8	66

131	Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. *Expert Opinion on Drug Discovery*, **2011**, 6, 811-25	6.2	61
130	Analytical pharmacology: the impact of numbers on pharmacology. *Trends in Pharmacological Sciences*, **2011**, 32, 189-96	13.2	29
129	Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. *Neuropharmacology*, **2011**, 60, 24-35	5.5	218
128	Impact of species variability and Probe-dependence on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. *British Journal of Pharmacology*, **2011**, 162, 1659-70	8.6	49
127	Allostery in GPCRs: MWC revisited. *Trends in Biochemical Sciences*, **2011**, 36, 663-72	10.3	55
126	Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 336, 540-50	4.7	63
125	Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. *Molecular Pharmacology*, **2011**, 80, 486-97	4.3	69
124	Quantification of functional selectivity at the human α_{1A}-adrenoceptor. *Molecular Pharmacology*, **2011**, 79, 298-307	4.3	64
123	The synthesis and biological evaluation of 2-amino-4,5,6,7,8,9-hexahydrocycloocta[b]thiophenes as allosteric modulators of the A1 adenosine receptor. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 3704-7	2.9	25
122	Quantification of allosteric interactions at G protein-coupled receptors using radioligand binding assays. *Current Protocols in Pharmacology*, **2011**, Chapter 1, Unit 1.22	4.1	11
121	The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor. *Molecular Pharmacology*, **2011**, 79, 855-65	4.3	24
120	Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with L-amino acids. *Journal of Biological Chemistry*, **2011**, 286, 8786-97	5.4	65
119	Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. *Clinical Science*, **2011**, 121, 297-303	6.5	209
118	H2 relaxin is a biased ligand relative to H3 relaxin at the relaxin family peptide receptor 3 (RXFP3). *Molecular Pharmacology*, **2010**, 77, 759-72	4.3	25
117	Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae. *Molecular Pharmacology*, **2010**, 78, 205-14	4.3	18
116	Delineating the mode of action of adenosine A1 receptor allosteric modulators. *Molecular Pharmacology*, **2010**, 78, 444-55	4.3	36
115	Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. *Molecular Pharmacology*, **2010**, 78, 94-104	4.3	57
114	Receptor activity modifying proteins and their potential as drug targets. *Progress in Molecular Biology and Translational Science*, **2010**, 91, 53-79	4	9

113	Effects of conformational restriction of 2-amino-3-benzoylthiophenes on A(1) adenosine receptor modulation. *Journal of Medicinal Chemistry*, **2010**, 53, 6550-9	8.3	27
112	Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. *Molecular Pharmacology*, **2010**, 78, 456-65	4.3	170
111	Detection of novel functional selectivity at M3 muscarinic acetylcholine receptors using a Saccharomyces cerevisiae platform. *ACS Chemical Biology*, **2010**, 5, 365-75	4.9	23
110	Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. *Journal of Biological Chemistry*, **2010**, 285, 7459-74	5.4	130
109	Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. *Neuropsychopharmacology*, **2010**, 35, 855-69	8.7	130
108	Overview of receptor allosterism. *Current Protocols in Pharmacology*, **2010**, Chapter 1, Unit 1.21	4.1	27
107	Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. *Journal of Biological Chemistry*, **2010**, 285, 19012-21	5.4	58
106	The Emergence of Allosteric Modulators for G Protein-Coupled Receptors **2010**, 61-87		3
105	The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling. *Brain Research*, **2010**, 1343, 153-67	3.7	43
104	Understanding Amylin Receptors **2010**, 41-57		3
103	Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 331, 775-86	4.7	34
102	Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor. *Molecular Pharmacology*, **2009**, 76, 264-74	4.3	44
101	Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. *FASEB Journal*, **2009**, 23, 442-50	0.9	123
100	Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 331, 277-86	4.7	42
99	Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 328, 893-9	4.7	37
98	Modulating receptor function through RAMPs: can they represent drug targets in themselves?. *Drug Discovery Today*, **2009**, 14, 413-9	8.8	48
97	Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. *Nature Reviews Drug Discovery*, **2009**, 8, 41-54	64.1	811
96	3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 7353-61	3.4	30

95	Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. *Journal of Medicinal Chemistry*, **2009**, 52, 4543-7	8.3	108
94	Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. *Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics*, **2009**, 9, 125-35		72
93	Homology modeling of GPCRs. *Methods in Molecular Biology*, **2009**, 552, 97-113	1.4	8
92	Pharmacology of 5HT(2C) receptor-mediated ERK1/2 phosphorylation: agonist-specific activation pathways and the impact of RNA editing. *Biochemical Pharmacology*, **2008**, 76, 1276-87	6	19
91	RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function **2008**, 119, 7-23		128
90	Synthesis and Cannabinoid Activity of a Variety of 2,3-Substituted 1-Benzo[b]thiophen Derivatives and 2,3-Substituted Benzofuran: Novel Agonists for the CB1 Receptor. *Australian Journal of Chemistry*, **2008**, 61, 484	1.2	5
89	The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors. *Regulatory Peptides*, **2008**, 145, 65-71		11
88	2-aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists. *Journal of Medicinal Chemistry*, **2008**, 51, 6165-72	8.3	47
87	New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). *Molecular Pharmacology*, **2008**, 74, 1119-31	4.3	96
86	Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. *Endocrinology*, **2008**, 149, 5423-31	4.8	113
85	Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 10978-83	11.5	185
84	Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. *Molecular Pharmacology*, **2008**, 74, 1059-71	4.3	58
83	A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. *Journal of Biological Chemistry*, **2008**, 283, 29312-21	5.4	147
82	The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 325, 927-34	4.7	10
81	Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. *Critical Care Medicine*, **2008**, 36, 1637-40	1.4	67
80	Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. *European Journal of Medicinal Chemistry*, **2008**, 43, 513-39	6.8	16
79	Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4401-4	2.9	17
78	Characterisation of the adenosine A1 receptor in Saccharomyces cerevisiae. *FASEB Journal*, **2008**, 22, 727.2	0.9	

77	Binding and functional characterisation of allosteric agonists at M2 muscarinic acetylcholine receptors. *FASEB Journal*, **2008**, 22, 724.6	0.9	
76	Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. *Molecular Pharmacology*, **2007**, 72, 463-76	4.3	98
75	Involvement of the sigma1 (sigma1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41. *British Journal of Pharmacology*, **2007**, 152, 267-79	8.6	21
74	Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. *Journal of Biological Chemistry*, **2007**, 282, 25677-86	5.4	122
73	Allosteric modulation of muscarinic acetylcholine receptors. *Current Neuropharmacology*, **2007**, 5, 157-67	7.6	93
72	Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 11927-32	11.5	89
71	Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. *Trends in Pharmacological Sciences*, **2007**, 28, 382-9	13.2	291
70	Functional selectivity and classical concepts of quantitative pharmacology. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 320, 1-13	4.7	870
69	Allosteric modulation of G protein-coupled receptors. *Annual Review of Pharmacology and Toxicology*, **2007**, 47, 1-51	17.9	549
68	Muscarinic Acetylcholine Receptors in the Central Nervous System: Structure, Function, and Pharmacology **2007**, 163-208		2
67	Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. *Current Pharmaceutical Design*, **2006**, 12, 1683-702	3.3	35
66	A critical role for the short intracellular C terminus in receptor activity-modifying protein function. *Molecular Pharmacology*, **2006**, 70, 1750-60	4.3	38
65	Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors. *Molecular Pharmacology*, **2006**, 69, 1984-9	4.3	49
64	Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoeth (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors--the role of receptor activity modifying protein 1. *Molecular Pharmacology*, **2006**, 69, 1984-91	4.3	78
63	Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. *Molecular Pharmacology*, **2006**, 70, 736-46	4.3	25
62	On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2. *Molecular Pharmacology*, **2006**, 69, 1441-53	4.3	43
61	Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. *Molecular Pharmacology*, **2006**, 69, 236-46	4.3	94
60	Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. *Trends in Pharmacological Sciences*, **2006**, 27, 475-81	13.2	106

59	Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs. *Annals of the New York Academy of Sciences*, **2006**, 1070, 90-104	6.5	64
58	Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. *Molecular Pharmacology*, **2005**, 67, 1655-65	4.3	177
57	"Ins and outs" of seven-transmembrane receptor signalling to ERK. *Trends in Endocrinology and Metabolism*, **2005**, 16, 26-33	8.8	78
56	Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. *Journal of Neurochemistry*, **2005**, 93, 1603-15	6	80
55	Effects of urea pretreatment on the binding properties of adenosine A1 receptors. *British Journal of Pharmacology*, **2005**, 146, 1119-29	8.6	11
54	Allosteric modulation of the cannabinoid CB1 receptor. *Molecular Pharmacology*, **2005**, 68, 1484-95	4.3	371
53	Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 312, 382-90	4.7	28
52	G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. *Circulation*, **2005**, 111, 1806-13	16.7	309
51	Evidence for pleiotropic signaling at the mouse beta3-adrenoceptor revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate]. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 312, 1064-74	4.7	34
50	Allosteric modulation of G protein-coupled receptors. *Current Pharmaceutical Design*, **2004**, 10, 2003-13	3.3	76
49	Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 308, 830-7	4.7	43
48	Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 308, 1062-72	4.7	48
47	The state of GPCR research in 2004. *Nature Reviews Drug Discovery*, **2004**, 3, 575, 577-626	64.1	70
46	Regulation of serotonin 5-HT2C receptors by chronic ligand exposure. *European Journal of Pharmacology*, **2004**, 498, 59-69	5.3	16
45	Effects of anandamide on the binding and signaling properties of M1 muscarinic acetylcholine receptors. *Biochemical Pharmacology*, **2004**, 68, 2207-19	6	17
44	Amylin receptors: molecular composition and pharmacology. *Biochemical Society Transactions*, **2004**, 32, 865-7	5.1	71
43	G-protein-coupled receptor allosterism: the promise and the problem(s). *Biochemical Society Transactions*, **2004**, 32, 873-7	5.1	45
42	Novel receptor partners and function of receptor activity-modifying proteins. *Journal of Biological Chemistry*, **2003**, 278, 3293-7	5.4	244

41	International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. *Pharmacological Reviews*, **2003**, 55, 597-606	22.5	430
40	RAMPs: 5 years on, where to now?. *Trends in Pharmacological Sciences*, **2003**, 24, 596-601	13.2	79
39	Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. *Trends in Pharmacological Sciences*, **2003**, 24, 580-8	13.2	335
38	Allosteric modulators of G-protein-coupled receptors. *Current Opinion in Pharmacology*, **2003**, 3, 551-6	5.1	65
37	Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. *Journal of Neurochemistry* , **2002**, 80, 1095-102	6	44
36	Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. *Nature Reviews Drug Discovery*, **2002**, 1, 198-210	64.1	514
35	Reversible and specific extracellular antagonism of receptor-histidine kinase signaling. *Journal of Biological Chemistry*, **2002**, 277, 6247-53	5.4	72
34	G protein-coupled receptor allosterism and complexing. *Pharmacological Reviews*, **2002**, 54, 323-74	22.5	740
33	From RaptiveRagonism to insurmountable antagonism: demonstrating the power of analytical pharmacology. *Clinical and Experimental Pharmacology and Physiology*, **2001**, 28, 223-9	3	6
32	Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. *British Journal of Pharmacology*, **2001**, 132, 1281-91	8.6	33
31	Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors. *Brain Research*, **2001**, 915, 70-8	3.7	35
30	The allosteric interaction of otenzepad (AF-DX 116) at muscarinic M2 receptors in guinea pig atria. *European Journal of Pharmacology*, **2001**, 416, 235-44	5.3	8
29	Non-surmountable antagonism: transcending steady state. *Trends in Pharmacological Sciences*, **2001** , 22, 65-66	13.2	5
28	Insurmountable AT1 receptor antagonism: message in a model?. *Trends in Pharmacological Sciences*, **2001**, 22, 555-7	13.2	6
27	Transducer abstraction: a novel approach to the detection of partial agonist efficacy in radioligand binding studies. *Journal of Pharmacological and Toxicological Methods*, **2000**, 43, 55-67	1.7	5
26	Further evidence for the heterogeneity of functional muscarinic receptors in guinea pig gallbladder. *European Journal of Pharmacology*, **2000**, 388, 115-23	5.3	7
25	Overview of Receptor Allosterism. *Current Protocols in Pharmacology*, **2000**, 11, 1.21.1	4.1	2
24	Beyond eyeballing: fitting models to experimental data. *Critical Reviews in Biochemistry and Molecular Biology*, **2000**, 35, 359-91	8.7	27

23	Quantification of Allosteric Interactions at G Protein Coupled Receptors Using Radioligand Binding Assays. *Current Protocols in Pharmacology*, **2000**, 11, 1.22.1	4.1	12
22	Dynamic mechanisms of non-classical antagonism by competitive AT(1) receptor antagonists. *Trends in Pharmacological Sciences*, **2000**, 21, 376-81	13.2	37
21	Beyond Eyeballing. *Handbooks of Pharmacology and Toxicology*, **2000**, 195-231		2
20	The generation of nitric oxide by G protein-coupled receptors. *Life Sciences*, **1999**, 64, 1-15	6.8	42
19	Characterization of the subtype selectivity of the allosteric modulator heptane-1,7-bis-(dimethyl-3Rphthalimidopropyl) ammonium bromide (C7/3-phth) at cloned muscarinic acetylcholine receptors. *Biochemical Pharmacology*, **1999**, 57, 171-9	6	32
18	Qualitative and quantitative assessment of relative agonist efficacy. *Biochemical Pharmacology*, **1999**, 58, 735-48	6	43
17	Regulation of acetylcholine binding by ATP at the muscarinic M(1) receptor in intact CHO cells. *Brain Research*, **1999**, 839, 94-9	3.7	5
16	The assessment of antagonist potency under conditions of transient response kinetics. *European Journal of Pharmacology*, **1999**, 382, 217-27	5.3	53
15	Allosteric interactions at muscarinic cholinoceptors. *Clinical and Experimental Pharmacology and Physiology*, **1998**, 25, 185-94	3	85
14	Use of a spreadsheet to quantitate the equilibrium binding of an allosteric modulator. *European Journal of Pharmacology*, **1998**, 355, 103-11	5.3	5
13	Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. *Trends in Pharmacological Sciences*, **1998**, 19, 351-7	13.2	160
12	Application of an allosteric ternary complex model to the technique of pharmacological resultant analysis. *Journal of Pharmacy and Pharmacology*, **1997**, 49, 781-6	4.8	15
11	Novel persistent activation of muscarinic M1 receptors by xanomeline. *European Journal of Pharmacology*, **1997**, 334, R3-4	5.3	14
10	Pharmacological analysis of the mode of interaction of McN-A-343 at atrial muscarinic M2 receptors. *European Journal of Pharmacology*, **1997**, 339, 153-6	5.3	15
9	Kinetic studies of co-operativity at atrial muscarinic M2 receptors with an "infinite dilution" procedure. *Biochemical Pharmacology*, **1997**, 53, 795-800	6	25
8	Interactions of agonists with an allosteric antagonist at muscarinic acetylcholine M2 receptors. *European Journal of Pharmacology*, **1996**, 316, 27-32	5.3	26
7	[3H]N-methylscopolamine dissociation from muscarine receptors affected by low concentrations of allosteric modulators. *European Journal of Pharmacology*, **1995**, 290, 259-62		5
6	Binding of the muscarine receptor antagonist heptane-1,7-bis(dimethyl-3Rphthalimidopropyl)ammonium bromide at cholinoceptor sites. *European Journal of Pharmacology*, **1993**, 246, 1-8		13

5	Cellular Signaling Mechanisms for Muscarinic Acetylcholine Receptors	82
4	Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation	3
3	Activation of M1 muscarinic receptors reduce pathology and slow progression of neurodegenerative disease	2
2	Measurement of Ligand-G Protein-Coupled Receptor Interactions1-29	
1	Second Messenger Assays for G Protein-Coupled Receptors: cAMP, Ca2+, Inositol Phosphates, ERK1/231-52	